ZNF615 Inhibitors
Chemical inhibitors of ZNF615 can employ various mechanisms to achieve functional inhibition. PD173074, an FGFR inhibitor, can disrupt the fibroblast growth factor receptor pathway, which is a signaling cascade that ZNF615 could be regulated by or influence. This disruption can lead to the functional inhibition of ZNF615, as its activity could be contingent upon signaling through this pathway. Similarly, LY294002 and Wortmannin are both PI3K inhibitors that can obstruct the PI3K/AKT pathway. ZNF615, potentially being regulated by or a part of this pathway, would be functionally inhibited if the pathway is blocked. U0126 targets MEK within the MAPK/ERK pathway, and the inhibition of MEK can lead to a halt in the activation of downstream proteins, which may include ZNF615. This results in the inhibition of ZNF615's function if it relies on the MAPK/ERK pathway for its activity or expression.
In parallel, the utilization of SP600125, a JNK pathway inhibitor, and SB203580, a p38 MAPK inhibitor, can impede pathways that ZNF615 may be involved in. By inhibiting these pathways, SP600125 and SB203580 can lead to the functional inhibition of ZNF615. Bortezomib, a proteasome inhibitor, can indirectly inhibit ZNF615 by causing the accumulation of regulatory proteins that may act as inhibitors of ZNF615, thereby reducing its functional activity. PP2, an Src kinase inhibitor, and Sorafenib, which inhibits multiple receptor tyrosine kinases, can disrupt various signaling cascades that may regulate ZNF615. These disruptions can lead to the functional inhibition of ZNF615 by preventing the activation or action of proteins that are critical to ZNF615's function. Lastly, Thapsigargin disrupts calcium homeostasis by inhibiting the SERCA pump, which can lead to the inhibition of calcium-dependent signaling pathways that regulate ZNF615, culminating in the functional inhibition of ZNF615.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
As an FGFR inhibitor, PD173074 can inhibit the fibroblast growth factor receptor pathway, a pathway that ZNF615 may influence or be influenced by, leading to the functional inhibition of ZNF615. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
This inhibitor targets Rho-associated protein kinase (ROCK), which could regulate the cytoskeletal architecture that ZNF615 might rely on for its spatial distribution or DNA-binding activity, resulting in the functional inhibition of ZNF615. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta receptor. Inhibition of the TGF-beta signaling can lead to downstream effects that include the functional inhibition of ZNF615, particularly if ZNF615 is involved in gene expression modulated by TGF-beta. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This chemical inhibits PI3K, which is involved in the AKT signaling pathway. If ZNF615 functions downstream or is regulated by PI3K/AKT signaling, LY294002's action can result in the functional inhibition of ZNF615. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, this compound can prevent the activation of downstream proteins that may include or regulate ZNF615, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor SP600125 can inhibit the JNK signaling pathway. If ZNF615's activity is modulated by JNK signaling, inhibition of this pathway can lead to the functional inhibition of ZNF615. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
As a p38 MAPK inhibitor, SB203580 can inhibit the p38 MAPK pathway. Since ZNF615 may be regulated by or associated with this pathway, inhibition by SB203580 can lead to its functional inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of regulatory proteins that may include inhibitors of ZNF615, resulting in the functional inhibition of ZNF615. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. It can inhibit the PI3K/AKT pathway, which may be necessary for ZNF615's function or regulation, thus leading to the functional inhibition of ZNF615. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src kinase inhibitor. Src kinases can regulate various signaling pathways that could include pathways regulating ZNF615, thus its inhibition can lead to functional inhibition of ZNF615. | ||||||